Cellens develops non-invasive cancer diagnostics using urine samples, nanoscale imaging, and machine learning to identify cancer-related changes in individual cells’ physical and mechanical properties
Cellens develops non-invasive cancer diagnostics using urine samples, nanoscale imaging, and machine learning to identify cancer-related changes in individual cells’ physical and mechanical properties. Its lead product, Uro CytoSense, uses atomic force microscopy to support bladder cancer detection and recurrence monitoring, with development toward additional cancer types and at-home or mail-in monitoring tests.